Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(3)
•••
Comment by themagicboxon Apr 30, 2020 4:03pm
99 Views
Post# 30973165

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Update from Dan L Himself.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Update from Dan L Himself.LOL he said they talk about you on discord you retard!

JohnnySins wrote: Thanks for the link, I'll check it out. No no no post your email. I want proof or at least something better than your word. No need to be scared...! I am not here to judge, I am here to help everyone learn, and hopefully from you, to show something credible to others. Why would you not show your email to everyone? I'm confused now... you are going to withhold your only shred of evidence because...why? 

And I'm not on discord, only CEO... must be some other ? I'm the same spelling on here and on CEO. Aww are you upset now that I called you out and you have nothing to back you up? I'm sorry, I didn't mean to hurt your feelings, I only wanted to truth. If you want to shake up the weak hands in the future, try backing up your claims with something more credible. ;) 


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities